Skip to main content

Table 1 MTHFR C677T genotype distribution among breast cancers and controls

From: Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer

   Alanine/Alanine Alanine/Valine Valine/Valine Alanine/Valine or Valine/Valine  
Group Number of cases No. (%) P valuea (OR, 95% CI) No. (%) P valuea (OR, 95% CI) No. (%) P valuea (OR, 95% CI) No. (%) P valuea (OR, 95% CI) Valine allele frequency
Controls 233 118 (50.6)   92 (39.5)   23 (9.9)     0.30
All breast cancer 335 140 (41.8) 1.00 162 (48.4) 0.03 (1.5, 1.0–2.1) 33 (9.8) 0.55 (1.2, 0.7–2.2) 195 (58.2) 0.04 (1.43, 1.02–2.00) 0.34
Under 40 breast cancer 203 78 (38.4) 1.00 104 (51.2) 0.01 (1.7, 1.2–2.6) 21 (10.4) 0.39 (1.4, 0.7–2.7) 125 (61.6) 0.01 (1.64, 1.12–2.41) 0.36
Familial and/or bilateral breast cancer 132 62 (47.0) 1.00 58 (43.9) 0.49 (1.2, 0.8–1.9) 12 (9.1) 1.00 (1.0, 0.5–2.1) 70 (53.0) 0.51 (1.16, 0.75–1.76) 0.31
  1. aFisher's exact test (two-sided) for the relevant genotype using the Alanine/Alanine homozygotes as reference. The odds ratio (OR) and 95% confidence intervals (CI) are shown in parentheses.